DD if that is correct, then it is interesting to note that MNTA's lawsuit which was intended for business purposes, has actually hurt their business as far as PPS goes and the general sentiment of MNTA reatining sole generic (at least in the very short term).
<<I suspect that Teva asked the FDA for some kind of written response by the end of January because Teva has to answer NVS/MNTA’s patent-infringement complaint in the US District Court in early February. >>
I don't think so. The answer was due in early January but on December 17th time to answer was extended to January 19 (see Dewophile's message below), which is when it was filed.
Market Data 
Markets 
AI
